Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have earned an average recommendation of “Hold” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $27.00.

A number of equities analysts have recently issued reports on FLGT shares. Zacks Research cut shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Thursday, January 22nd. Wall Street Zen lowered Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $15.00 target price (down from $30.00) on shares of Fulgent Genetics in a research report on Tuesday, May 5th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC lifted its position in shares of Fulgent Genetics by 69.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after purchasing an additional 548 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in Fulgent Genetics in the fourth quarter valued at approximately $35,000. Caitong International Asset Management Co. Ltd lifted its stake in Fulgent Genetics by 214.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after purchasing an additional 1,251 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Fulgent Genetics in the 2nd quarter valued at about $49,000. Finally, Flagship Harbor Advisors LLC bought a new stake in Fulgent Genetics in the 4th quarter valued at about $56,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Stock Performance

FLGT stock opened at $15.70 on Monday. The firm has a market cap of $467.08 million, a PE ratio of -6.57 and a beta of 0.88. Fulgent Genetics has a 1-year low of $13.46 and a 1-year high of $31.04. The stock has a 50-day moving average price of $15.62 and a 200-day moving average price of $22.33.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Friday, February 27th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.02 by $0.14. The company had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics had a negative net margin of 23.04% and a negative return on equity of 3.24%. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. On average, analysts forecast that Fulgent Genetics will post -2.81 earnings per share for the current year.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.